Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Uracil mustard revisited.

B J Kennedy1, J L Torkelson, E Torlakovic

  • 1Department of Medicine, University of Minnesota Medical School, Fairview-University Medical Center, Minneapolis 55455, USA.

Cancer
|May 18, 1999
PubMed
Summary

Uracil mustard, an oral alkylating agent, showed significant effectiveness in treating lymphoma and leukemia patients. This inexpensive drug demonstrated notable response rates and warrants reevaluation for modern therapeutic use.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biomarker testing in oncology - Requirements for organizing external quality assessment programs to improve the performance of laboratory testing: revision of an expert opinion paper on behalf of IQNPath ABSL.

Virchows Archiv : an international journal of pathology·2020
Same author

Crizotinib inhibition of <i>ROS1-</i>positive tumours in advanced non-small-cell lung cancer: a Canadian perspective.

Current oncology (Toronto, Ont.)·2019
Same author

Nb K-edge x-ray absorption investigation of the pressure induced amorphization in A-site deficient double perovskite La1/3NbO3.

Journal of physics. Condensed matter : an Institute of Physics journal·2016
Same author

Dominant-negative Ikaros cooperates with BCR-ABL1 to induce human acute myeloid leukemia in xenografts.

Leukemia·2014
Same author

X-ray microdiffraction, TEM characterization and texture analysis of human dentin and enamel.

Journal of microscopy·2013
Same author

Elastic anomalies associated with transformation sequences in perovskites: II. The strontium zirconate-titanate Sr(Zr,Ti)O(3) solid solution series.

Journal of physics. Condensed matter : an Institute of Physics journal·2011

Area of Science:

  • Oncology
  • Hematology
  • Pharmacology

Background:

  • A long-term remission in a diffuse large cell lymphoma patient treated with uracil mustard prompted this study.
  • Uracil mustard is an oral alkylating agent that was used in cancer treatment historically.

Purpose of the Study:

  • To review the efficacy and toxicity of uracil mustard in patients treated between 1958 and 1970.
  • To assess the historical effectiveness of uracil mustard for various hematologic malignancies.

Main Methods:

  • Retrospective review of patient records treated with uracil mustard from 1958-1970.
  • Histologic review using the International Formulation criteria where possible.
  • Analysis of treatment response rates and toxicity, primarily thrombocytopenia.

Main Results:

  • High overall regression rates were observed: 69.2% in non-Hodgkin lymphoma, 69.4% in Hodgkin disease, and 74% in chronic lymphatic leukemia.
  • Complete response rates varied, with 23.4% in non-Hodgkin lymphoma and 7.7% in chronic lymphatic leukemia.
  • Thrombocytopenia was identified as the main toxicity associated with uracil mustard treatment.

Conclusions:

  • Uracil mustard demonstrated significant efficacy in treating lymphoma, chronic lymphatic leukemia, and thrombocythemia.
  • The drug is inexpensive and administered orally, suggesting potential for reevaluation in current clinical practice.
  • Historical data indicate uracil mustard as a viable, cost-effective therapeutic option for specific hematologic conditions.

Related Experiment Videos